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Abstract
Objective To evaluate the 104-week safety of dapagli-
flozin in older patients with type 2 diabetes mellitus.
Methods Pooled analysis assessing general safety (nine
phase III studies B104 weeks) and cardiovascular safety
(21 phase IIb/III studies B208 weeks) by age (\65; C65;
C75 years). Patients with type 2 diabetes mellitus
(±background glucose-lowering therapy) received: dapa-
gliflozin 10 mg (n = 2026) vs. placebo (n = 1956) (nine-
study pool); or dapagliflozin (2.5–50 mg; n = 5936) vs.
control (placebo/comparator) (n = 3403) (21-study pool).
Results Adverse events (AEs) and discontinuations owing
to AEs were more common in older vs. younger patients,
and were more frequent with dapagliflozin than placebo
(AEs: \65 years: 73.1 vs. 70.7 %; C65 years: 77.4 vs.
73.1 %; C75 years: 80.4 vs. 75.3 %, respectively; discon-
tinuations:\65 years: 5.9 vs. 5.0 %; C65 years: 14.4 vs.
12.2 %; C75 years: 26.8 vs. 22.1 %, respectively); serious
AE (SAE) frequency was similar (\65 years: 11.0 vs.
11.8 %; C65 years: 20.0 vs. 20.2 %; C75 years: 19.6 vs.
18.2 %, respectively). Hypoglycaemia frequency was
similar across age groups and was higher with dapagliflozin
than placebo (\65 years: 18.0 vs. 13.4 %; C65 years: 20.2
vs. 17.7 %; C75 years: 17.5 vs. 16.9 %, respectively);
major episodes were rare. Urinary tract infection frequency
was similar between treatment groups in older patients,
with no increase vs. younger patients (\65 years: 8.8 vs.
5.5 %; C65 years: 8.1 vs. 7.6 %; C75 years: 8.2 vs. 9.1 %,
respectively); urinary tract infection SAEs were rare.
Genital infection AEs were more common with dapagli-
flozin, with no increase in older patients (\65 years: 8.2 vs.
1.0 %; C65 years: 6.6 vs. 0.9 %; C75 years: 7.2 vs. 0.0 %,
respectively) and no SAEs. Volume reduction AEs were
uncommon, with a higher frequency with dapagliflozin vs.
placebo and in patients C75 years (\65 years: 1.7 vs.
1.2 %; C65 years: 2.3 vs. 1.7 %; C75 years: 3.1 vs. 2.6 %,
respectively). Dapagliflozin did not increase the risk of
fractures (\65 years: 1.1 vs. 1.1 %; C65 years: 1.1 vs.
2.7 %; C75 years: 1.0 vs. 2.6 %, respectively) or falls
(\65 years: 0.7 vs. 0.7 %; C65 years: 0.6 vs. 2.1 %;
C75 years: 0.0 vs. 1.3 %, respectively), regardless of age.
AEs of renal function were more common with dapagli-
flozin than placebo and increased with age (\65 years: 3.5
vs. 2.3 %; C65 years: 14.0 vs. 7.9 %; C75 years: 29.9 vs.
20.8 %, respectively). Most were non-serious small tran-
sient increases in serum creatinine. Dapagliflozin did not
increase cardiovascular risk regardless of age [hazard ratio
(95 % confidence interval) vs. control: \65 years: 0.726
(0.473, 1.114); C65 years: 0.879 (0.565, 1.366);
C75 years: 0.950 (0.345, 2.617), respectively].
Conclusion Dapagliflozin treatment up to 104 weeks was
well tolerated in older patients. Older dapagliflozin-treated
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patients had more renal AEs than placebo-treated patients;
the majority of which were non-serious small transient
changes in serum creatinine.
Key Points
The long-term safety of dapagliflozin was similar
between older and younger patients, with
comparable rates of hypoglycaemia, genital
infections and urinary tract infections, low rates of
volume reduction, and no increased risk of bone
fractures or falls.
Adverse events of renal function were more frequent
in patients receiving dapagliflozin and in older vs.
younger patients; the majority of cases were non-
serious and driven by small transient changes in
serum creatinine.
Dapagliflozin did not increase the risk of
cardiovascular disease in older or younger patients.
1 Introduction
The prevalence of type 2 diabetes mellitus (T2DM) is
increasing globally, with the highest increases estimated
amongst older populations [1].A4.5-fold increase in diabetes is
predicted between 2005 and 2050 in people aged C65 years,
compared with a 3-fold rise in the overall population [2].
Polypharmacy [3] and multiple comorbidities [4, 5]
among older patients with T2DM present a number of
challenges in terms of the clinical management of this
patient group. In addition, pharmacokinetic and pharma-
codynamic changes associated with ageing may increase
the risk of adverse events (AEs) among this age group [5],
including hypoglycaemia, volume reduction, impaired
renal function and cardiovascular disease [6–8]. The
increased susceptibility to hypoglycaemia among older
people [9] is of particular concern because of the associated
increased risk of falls and bone fractures [10].
Certain therapies may be less appropriate for some older
patients, such as those associated with a higher risk of
hypoglycaemia (e.g. sulphonylurea or insulin) [6]. Fur-
thermore, complex dosing regimens for glycaemic control
are not favoured. A once-daily oral medication regimen
that can be taken at any time of day with or without food,
with a low risk of hypoglycaemia and a well-characterised
predictable safety profile, would be preferable.
Novel glucose-lowering therapies are required to
address the unmet needs in the treatment of older patients
with T2DM. Dapagliflozin is a highly selective sodium
glucose co-transporter 2 (SGLT2) inhibitor that, in addition
to reducing glycosylated haemoglobin (HbA1c), body
weight and systolic blood pressure [11–14], is associated
with a low intrinsic risk of hypoglycaemia [16], and
showed no increase in cardiovascular risk in a recent meta-
analysis [15]. These benefits combined with its once-daily
oral dosing regimen [17] suggest it may be a useful treat-
ment in the management of older patients with T2DM.
Identified risks include genital infections and, to a lesser
extent, urinary tract infections and non-serious volume-
related events; all of which are consistent with the mech-
anism of action of dapagliflozin and are mostly of mild
intensity [16].
Here, we present a pooled analysis of nine phase III
studies to assess the long-term safety of dapagliflozin in
older patients with T2DM. In addition, we present a pooled
analysis of 21 phase IIb/III studies to assess the cardio-




Safety and efficacy were evaluated by age group [\65, C65
and C75 years (a subpopulation of the C65 years age
group; safety only)] in a placebo-controlled pool of nine
double-blind phase III studies of B104 weeks in duration,
in which patients with T2DM received dapagliflozin 10 mg
(n = 2026) or placebo (n = 1956) ± background glucose-
lowering therapy (Online Resource 1).
Cardiovascular events were evaluated by age group
[\65, C65 and C75 years (a subpopulation of the
C65 years age group)], using data from a pre-specified
cardiovascular meta-analysis of 21 phase IIb/III studies of
B208 weeks in duration, in which patients with T2DM
received dapagliflozin (2.5, 5, 10, 20 or 50 mg; n = 5936)
or control (placebo or comparator treatment;
n = 3403) ± background glucose-lowering therapy (On-
line Resource 2). Studies with at least one adjudicated
cardiovascular event were included in the analysis.
These two different patient pools were each selected to
address a specific objective. The nine-study pool was
considered to be the most appropriate to assess general
safety because all trials were long term (with at least
48 weeks of blinded study treatment) and placebo con-
trolled. In contrast, the 21-study pool with high patient
numbers was considered to be the most appropriate to
assess the cardiovascular profile of dapagliflozin because
cardiovascular events were relatively infrequent. The nine-
study safety pool examined dapagliflozin 10 mg (the usual
recommended clinical dose), whereas the 21-study
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cardiovascular pool examined all dapagliflozin doses (2.5,
5, 10, 20 and 50 mg). Methods for each individual study in
these pools have been published previously
[11–14, 18–32]. All studies were conducted according to
the principles of the Declaration of Helsinki and the
requirements of Good Clinical Practice, and were approved
by the relevant institutional review boards/ethics commit-
tees. All participants gave written informed consent.
2.2 General Safety Outcomes
2.2.1 Adverse Events
The frequency of overall AEs and serious AEs (SAEs) was
evaluated according to age group up to 104 weeks.
2.2.2 Adverse Events of Special Interest
The proportion of patients with any event of hypogly-
caemia was assessed by age and according to background
medication, up to 104 weeks.
The frequency of AEs of genital infection, urinary tract
infection (UTI), volume reduction (defined as hypotension,
dehydration or hypovolaemia), bone fracture, fall and renal
function were evaluated by age group up to 104 weeks,
based on pre-defined lists of preferred terms from the Med-
ical Dictionary of Regulatory Activities (version 15.1) (On-
lineResource 3). Reports of genital infections andUTIswere
obtained through proactive questioning and spontaneous
reporting. Calculation of estimated glomerular filtration rate
(eGFR) used the Abbreviated Modification of Diet in Renal
Disease Study equation [33]. Mean change from baseline in
eGFR was determined for each age group up to 104 weeks,
as were the maximum changes from baseline in serum cre-
atinine in patients with at least one AE of renal function.
2.2.3 Laboratory Values
The frequency of marked abnormalities (MAs) in labora-
tory values was assessed for each age category up to
104 weeks. Laboratory assessments comprised the fol-
lowing: serum calcium, serum bicarbonate, serum potas-
sium, serum magnesium, serum sodium, inorganic
phosphorus, haematocrit, blood urea nitrogen and serum
creatinine.
2.3 Efficacy Outcomes
2.3.1 HbA1c, Body Weight and Systolic Blood Pressure
Efficacy assessments for each age group comprised the
mean change from baseline in HbA1c, the proportion of
patients achieving an HbA1c level of \53 mmol/mol
(\7 %) and the mean change from baseline in body weight
and systolic blood pressure (SBP), up to 104 weeks.
2.4 Analysis Method
Analyses were conducted using descriptive statistics only.
Comparisons with placebo were adjusted for differences in
baseline values between groups. Analyses were performed
using all available data regardless of rescue therapy, with
the exception of hypoglycaemia and efficacy data [change
from baseline in HbA1c, body weight and SBP, and the
proportion of patients achieving an HbA1c level of
\53 mmol/mol (\7 %)], which excluded data after the
initiation of rescue therapy. Confidence intervals (CIs) for
the proportion of patients achieving an HbA1c level of
\53 mmol/mol (\7 %) were estimated using logistic
regression modelling for the difference between treatment
groups.
2.5 Cardiovascular Safety
A meta-analysis was conducted according to age group to
assess the cardiovascular risk for the pooled population of
21 phase IIb/III studies of B208 weeks in duration, using
the composite endpoint of ‘cardiovascular death, myocar-
dial infarction, stroke and hospitalisation for unstable ang-
ina’. All cardiovascular events were independently
adjudicated in a blinded manner. The analyses were con-
ducted without statistical hypothesis testing. Hazard ratios
(HRs) and 95 % CIs comparing total dapagliflozin doses
(2.5, 5, 10, 20 and 50 mg) with a control (placebo or
comparator treatment) were calculated for each age group
using the Cox proportional hazards model. An upper limit
of the 95 % CI of\1 (the null value) would indicate that
dapagliflozin was associated with a lower cardiovascular
risk than placebo, whereas a lower limit of the 95 % CI of
[1 would indicate that dapagliflozin was associated with a
higher cardiovascular risk than placebo.
3 Results
3.1 Patients
Demographics and baseline characteristics for the nine
pooled studies were generally balanced between the
dapagliflozin and placebo groups in patients aged\65 and
C65 years (Table 1). Some differences were observed
between the treatment groups in patients aged C75 years
(Table 1), which may reflect the small sample size for this
age group (n = 97 for dapagliflozin vs. n = 77 for pla-
cebo) and random variation within the C75 years dataset
rather than significant differences between the groups.
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Older patients (C65 or C75 years) had a relatively longer
T2DM duration, higher systolic blood pressure and lower
eGFR levels at baseline than younger patients (\65 years)
(Table 1).
3.2 Overall Adverse Events
Overall AEs and discontinuations owing to AEs were more
common in patients aged C65 and C75 years than in
patients aged \65 years, and were more frequent with
dapagliflozin than placebo (Table 2). The frequency of
SAEs was similar between the treatment groups across all
ages, and more frequent in older vs. younger patients. In
total, 30 deaths were reported in the nine pooled studies;
18/2026 (0.9 %) in the dapagliflozin group and 12/1956
(0.6 %) in the placebo group (Table 2), none of which
were considered related to treatment. Further information
regarding these deaths is provided in Online Resource 4.
3.3 Adverse Events of Special Interest
3.3.1 Hypoglycaemia
The frequency of hypoglycaemia was similar between
younger patients (aged\65 years) and older patients (aged
C65 or C75 years), and more frequent with dapagliflozin
than placebo, with major hypoglycaemic episodes being
rare in all treatment groups (Table 2). In patients receiving
Table 1 Demographic and baseline characteristics by age group












10 mg (n = 97)
Placebo
(n = 77)
Mean age, years (SD) 54.6 (7.5) 54.8 (7.5) 69.9 (4.0) 69.7 (4.0) 77.1 (1.8) 77.8 (2.8)
Female, n (%) 624 (44.4) 545 (41.9) 228 (36.8) 254 (38.8) 43 (44.3) 31 (40.3)
Race, n (%)
Caucasian 1179 (83.9) 1090 (83.8) 560 (90.3) 605 (92.4) 90 (92.8) 72 (93.5)
Asian 96 (6.8) 94 (7.2) 35 (5.6) 26 (4.0) 6 (6.2) 3 (3.9)
Black/African American 57 (4.1) 50 (3.8) 9 (1.5) 11 (1.7) 1 (1.0) 1 (1.3)
Other 74 (5.3) 67 (5.1) 16 (2.6) 13 (2.0) 0 1 (1.3)
Mean time from T2DM diagnosis, years (SD) 8.3 (7.3) 8.3 (7.0) 13.2 (8.9) 12.7 (8.8) 15.4 (10.2) 14.9 (10.0)
Mean HbA1c, mmol/mol (SD) 65 (9.6) 65 (9.5) 64 (8.9) 64 (8.7) 65 (8.6) 62 (7.4)
Mean FPG, mmol/L (SD) 9.1 (2.5) 9.2 (2.5) 8.9 (2.5) 8.8 (2.3) 8.8 (2.3) 8.6 (2.0)
Mean weight, kg (SD) 92.1 (20.3) 91.6 (19.9) 89.3 (17.8) 89.5 (17.1) 84.9 (13.7) 88.2 (15.1)
Mean BMI, kg/m2 (SD) 32.8 (5.9) 32.5 (6.0) 31.7 (4.9) 32.0 (5.2) 30.7 (4.6) 31.9 (4.6)
Mean systolic BP, mmHg (SD) 130.5 (15.2) 130.1 (15.0) 135.7 (14.7) 135.5 (13.9) 138.7 (14.5) 133.3 (13.8)
Systolic BP, n (%)
C130 mmHg 738 (52.5) 677 (52.0) 415 (66.9) 427 (65.2) 71 (73.2) 49 (63.6)
Mean eGFR, mL/min/1.73 m2 (SD) 84.6 (19.0) 84.3 (19.2) 72.8 (16.7) 73.4 (16.9) 72.6 (16.2) 68.6 (16.5)
eGFR, n (%)
\30 mL/min/1.73 m2b 0 1 (0.1) 1 (0.2) 0 0 0
C30 to\60 mL/min/1.73 m2c 117 (8.3) 108 (8.3) 134 (21.6) 141 (21.5) 22 (22.7) 22 (28.6)
C60 to\90 mL/min/1.73 m2d 754 (53.6) 710 (54.6) 386 (62.3) 403 (61.5) 57 (58.8) 47 (61.0)
C90 mL/min/1.73 m2e 535 (38.1) 481 (37.0) 99 (16.0) 111 (16.9) 18 (18.6) 8 (10.4)
Mean serum creatinine, lmol/L (SD) 77.5 (18.7) 78.3 (20.9) 85.8 (21.8) 84.7 (19.5) 82.4 (18.3) 87.9 (20.2)
Data available up to 104 weeks
BMI body mass index, BP blood pressure, eGFR estimated glomerular filtration rate, FPG fasting plasma glucose, HbA1c glycosylated hae-
moglobin, SD standard deviation, T2DM type 2 diabetes mellitus
a Subpopulation of the C65 years age group
b Severe renal impairment
c Moderate renal impairment
d Mild renal impairment
e Normal renal function
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dapagliflozin as monotherapy or in combination with
metformin, a thiazolidinedione or a dipeptidyl peptidase-4
inhibitor, the frequency of hypoglycaemia with dapagli-
flozin was similar to placebo for all age groups (Online
Resource 5). Hypoglycaemia was more common in studies
where treatment was combined with insulin or a sulpho-
nylurea, with comparatively higher rates in dapagliflozin-
treated patients than in placebo-treated patients.
3.3.2 Genital Infection and Urinary Tract Infection
Events of genital infection occurred more frequently with
dapagliflozin than placebo but did not substantially differ
between age groups (Table 2). Events were more common
among female patients regardless of age. All AEs of genital
infection were reported to be mild or moderate in intensity
and responded to standard treatment.
Table 2 Adverse events by age group
n (%) Age\65 years Age C65 years Age C75 yearsa
Dapagliflozin












All 1028 (73.1) 920 (70.7) 480 (77.4) 479 (73.1) 78 (80.4) 58 (75.3)
AE leading to discontinuation 83 (5.9) 65 (5.0) 89 (14.4) 80 (12.2) 26 (26.8) 17 (22.1)
Any SAEb 154 (11.0) 154 (11.8) 124 (20.0) 132 (20.2) 19 (19.6) 14 (18.2)
Deaths 7 (0.5) 7 (0.5) 11 (1.8) 5 (0.8) 2 (2.0) 1 (1.3)
AEs of special interest
Hypoglycaemia
All 253 (18.0) 174 (13.4) 125 (20.2) 116 (17.7) 17 (17.5) 13 (16.9)
Major episodesc 2 (0.1) 2 (0.2) 2 (0.3) 0 0 0
Genital infection
All 115 (8.2) 13 (1.0) 41 (6.6) 6 (0.9) 7 (7.2) 0
Female 78 (12.5) 12 (2.2) 20 (8.8) 3 (1.2) 6 (14.0) 0
Male 37 (4.7) 1 (0.1) 21 (5.4) 3 (0.7) 1 (1.9) 0
SAEsb 0 0 0 0 0 0
Urinary tract infection
All 124 (8.8) 71 (5.5) 50 (8.1) 50 (7.6) 8 (8.2) 7 (9.1)
Female 93 (14.9) 52 (9.5) 28 (12.3) 34 (13.4) 4 (9.3) 5 (16.1)
Male 31 (4.0) 19 (2.5) 22 (5.6) 16 (4.0) 4 (7.4) 2 (4.3)
SAEsb 3 (0.2) 2 (0.2) 2 (0.3) 1 (0.2) 1 (1.0) 0
Pyelonephritis 2 (0.1) 1 (0.1) 1 (0.2) 2 (0.3) 0 0
Volume reductiond
All 24 (1.7) 16 (1.2) 14 (2.3) 11 (1.7) 3 (3.1) 2 (2.6)
SAEsb 1 (\0.1) 3 (0.2) 2 (0.3) 3 (0.4) 0 1 (1.3)
Syncope 1 (\0.1) 2 (0.2) 1 (0.2) 3 (0.5) 0 1 (1.3)
Circulatory collapse 0 1 (\0.1) 1 (0.2) 0 0 0
Renal function
All 49 (3.5) 30 (2.3) 87 (14.0) 52 (7.9) 29 (29.9) 16 (20.8)
SAEsb 4 (0.3) 1 (0.1) 1 (0.2) 2 (0.3) 1 (1.3) 0
Data available up to 104 weeks. All results included data after rescue therapy, apart from hypoglycaemia for which data after rescue therapy
were excluded
AE adverse event, N total number of patients, n number of patients with an AE, SAE serious adverse event
a Subpopulation of the C65 years age group
b Based on the International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use
definition
c Symptomatic episode requiring external assistance, with a capillary or plasma glucose value\54 mg/dL (3 mmol/L) and prompt recovery after
glucose or glucagon administration
d Hypotension, dehydration or hypovolaemia
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Although AEs of UTI were more common with dapa-
gliflozin than placebo treatment in patients aged
\65 years, frequencies were similar between treatment
groups in patients aged C65 and C75 years (Table 2) and
did not increase with age. AEs of UTI were more common
among female patients. Most events of UTI were reported
to be of mild or moderate intensity, and SAEs were rare
for all age groups. Few cases of pyelonephritis were
reported with dapagliflozin or placebo, regardless of age
(Table 2).
3.3.3 Volume Reduction
The frequency of AEs of volume reduction was low in both
treatment arms across all age groups, with a small increase
in events with dapagliflozin and in patients aged C75 years
(Table 2). Most volume reduction AEs were reported as
hypotension or syncope. The majority of AEs of volume
reduction were mild or moderate in intensity, did not
require intervention and had resolved within 28 days
[number of events (%) with a duration [28 days: \65
years: n = 8/30 (26.7 %) vs. n = 0/17 (0.0 %); C65 years:
n = 2/17 (11.8 %) vs. n = 0/12 (0.0. %); C75 years:
n = 1/5 (20.0 %) vs. n = 0/2 (0.0 %), with dapagliflozin
vs. placebo, respectively]. Few SAEs of volume reduction
were reported in either treatment group, without any
obvious imbalance between groups; most SAEs were
reported as syncope (Table 2).
3.3.4 Renal Function
Renal function remained stable over time in patients treated
with dapagliflozin (Fig. 1). In younger patients, eGFR
returned to baseline within a few weeks of treatment after a
small early reduction with dapagliflozin vs. placebo (-4.0
vs. 0.1 mL/min/1.73 m2 at week 1, respectively). In older
patients, the initial reduction in eGFR was of a similar
magnitude to younger patients (C65 years: -4.7 vs.
0.9 mL/min/1.73 m2 at week 1; C75 years: -5.2 vs.
0.4 mL/min/1.73 m2 at week 4, with dapagliflozin and
placebo, respectively); however, recovery of eGFR
appeared slower, and levels remained below baseline but
were stable up to 102 weeks. Interestingly, after the first
24 weeks of treatment, eGFR values were superimposable
in patients receiving dapagliflozin and placebo (Fig. 1).
AEs of renal function were more common with dapa-
gliflozin (Table 2) and the frequency of events increased
with age in both treatment groups. Most AEs of renal
function were reports of increased creatinine levels,
reduced creatinine clearance, renal impairment or reduced
eGFR. Few SAEs of renal function were reported.
The distribution of serum creatinine changes in patients
with a reported AE of renal function was similar between
the treatment groups in patients aged\65 and C65 years,
with a higher frequency of minor, transient serum crea-
tinine changes (9 to B27 lmol/L) reported with dapagli-
flozin in patients aged C75 years (Fig. 2).
MAs of serum creatinine of C133 lmol/L were more
frequent in older vs. younger patients, with a similar fre-
quency between the dapagliflozin and placebo groups
(Online Resource 6). MAs of serum creatinine of
C221 lmol/L were uncommon in all age groups. MAs of
blood urea nitrogen were balanced between the treatment
groups regardless of age.
3.4 Bone Fractures, Falls and Non-renal
Laboratory Abnormalities
The frequency of fractures was numerically similar or lower
with dapagliflozin vs. placebo for all age groups [\65 years:
16 (1.1 %) vs. 14 (1.1 %); C65 years: 7 (1.1 %) vs. 18
(2.7 %); C75 years: 1 (1.0 %) vs. 2 (2.6 %), respectively].
Dapagliflozin was not associated with an increased risk of
falls compared with placebo in any age category [\65 years:
10 (0.7 %) vs. 9 (0.7 %); C65 years: 4 (0.6 %) vs. 14
(2.1 %); C75 years: 0 vs. 1 (1.3 %), respectively).
Electrolyte abnormalities were infrequent, and MAs in
serum calcium, serum bicarbonate, serum magnesium and
serum sodium were balanced between the treatment arms
and across age groups (Online Resource 6). Dapagliflozin
was associated with a higher frequency of serum potassium
MAs of C6.0 mmol/L than placebo in older but not
younger patients (Online Resource 6). No cases of serum
potassium MAs of B2.5 mmol/L were reported. MAs of
inorganic phosphorus (C1.81 mmol/L) were more common
with dapagliflozin and were more common in older vs.
younger patients (Online Resource 6). MAs of haematocrit




Dapagliflozin was associated with a greater reduction from
baseline in HbA1c up to 104 weeks compared with placebo
in both patients aged\65 and those aged C65 years (On-
line Resource 7). A significantly greater proportion of
patients achieved an HbA1c value of \53 mmol/mol
(\7 %), with dapagliflozin vs. placebo in both age groups
(\65 years: 25.6 vs. 15.2 %; C65 years: 18.2 vs. 12.3 %).
As such, the efficacy of dapagliflozin in reducing HbA1c
was similar in older vs. younger patients.









































Dapagliflozin 10 mg;BL mean (SD): 72.8 (16.7) mL/min/1.73 m2
Placebo; BL mean (SD): 73.5 (16.9) mL/min/1.73 m2





























































Dapagliflozin 10 mg;BL mean (SD): 72.6 (16.2) mL/min/1.73 m2
Placebo; BL mean (SD): 68.6 (16.5) mL/min/1.73 m2




























































Dapagliflozin 10 mg; BL mean (SD): 84.6 (19.0) mL/min/1.73 m2
Placebo; BL mean (SD): 84.3 (19.2) mL/min/1.73 m2




















Fig. 1 Mean changes from
baseline in eGFR over time by
age group. Data available up to
102 weeks; includes data after
rescue therapy. BL baseline, CI
confidence interval, eGFR
estimated glomerular filtration
rate, SD standard deviation.
aSubpopulation of the
C65 years age group
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3.5.2 Body Weight and Systolic Blood Pressure
For both patients aged \65 years and those aged
C65 years, reductions in body weight were greater with
dapagliflozin than with placebo up to 104 weeks (Online
Resource 8). SBP reduction was more pronounced with
dapagliflozin compared with placebo in both age cate-
gories, although absolute changes were generally small
(Online Resource 9).
3.6 Cardiovascular Risk
In the 21-study cardiovascular meta-analysis of
B208 weeks [dapagliflozin, n = 5936 vs. control (placebo
or comparator treatment), n = 3403], the HR for the
composite endpoint of ‘cardiovascular death, myocardial
infarction, stroke and hospitalisation for unstable angina’
was \1 for dapagliflozin vs. control in all age groups
(Fig. 3), indicating that dapagliflozin does not increase the
risk of cardiovascular disease in these patients.
4 Discussion
This pooled analysis of nine phase III studies investigated
the safety profile of dapagliflozin across age subgroups.
Dapagliflozin 10 mg was generally well tolerated in both
younger and older patients with T2DM during the 2-year
treatment period. As expected, dapagliflozin was shown to
reduce HbA1c, body weight and SBP compared with pla-
cebo across age groups.
Despite the fact that older patients are at higher risk of
hypoglycaemia [8], rates were generally comparable across
all ages, with a higher frequency in the dapagliflozin group
compared with the placebo group. Of note, older patients
treated with dapagliflozin either as monotherapy or in
combination with metformin, a thiazolidinedione or a
dipeptidyl peptidase-4 inhibitor had a similar risk of
hypoglycaemia as placebo, in line with previous studies
showing that dapagliflozin is associated with a low intrinsic
hypoglycaemic risk [32, 34].
The increased risk of genital infections with dapagli-
flozin 10 mg relative to placebo is consistent with previous
observations of SGLT2 inhibitors [35], but frequencies did
not increase in older patients. These events are typical for
diabetes and the risk, presentation and treatment options
are familiar to both physicians and patients [36]. Further-
more, despite the fact that older people are more suscep-
tible to UTIs [37], rates did not increase in older patients in
the current analysis.
Dapagliflozin has a mild diuretic effect, and therefore
volume-related events are of special interest, especially in
older patients [17]. Older patients have an increased
propensity to develop volume reduction, which may be
attributed to changes in body composition with ageing,
leading to impairments in volume regulation and dysreg-
ulation of fluid intake [38]. Volume reduction may also be
exacerbated by the diuretic treatments taken by many older
patients [39]. AEs of volume reduction were more frequent
with dapagliflozin 10 mg than placebo, and were higher in
patients aged C75 years in both treatment groups. Most
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Fig. 2 Maximum change from baseline in serum creatinine in
patients with AEs of renal function, by age group. Data show the
proportion of patients with a maximum change from baseline in
serum creatinine in the range indicated. Data available up to
102 weeks; n is the number of patients with an AE of renal function;
N is the number of treated patients. Includes data after rescue therapy.
AE adverse event. aSubpopulation of the C65 years age group
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as hypotension with no intervention required, which is
consistent with previous reports [16], and the vast majority
of events were mild or moderate in intensity.
Renal function in older and younger patients treated
with dapagliflozin remained stable over time, with small
transient reductions in eGFR relative to placebo early on in
treatment. Similar to observations made in patients with
impaired renal function [25], eGFR levels did not com-
pletely return to baseline levels in older patients, after an
initial small drop in eGFR, which is consistent with the
mechanism of action of dapagliflozin. These early small
eGFR decreases followed by long-term stability across age
groups are likely related to tubuloglomerular feedback
responses and/or blood pressure reduction [40], and should
not lead to discontinuation of dapagliflozin treatment.
Ageing is associated with a progressive decline in eGFR
[38] and slower renal function recovery times [41], which
may be attributed to an impaired capacity for autoregula-
tion [42]. In the current analysis, the fact that eGFR levels
did not fully recover to baseline values in older patients,
irrespective of treatment group, is in keeping with the
reduced renal function in this population.
In view of the diuretic effect of dapagliflozin [26] and
some transient volume shifts, it is not surprising to see
elevations in serum creatinine, especially in patients with
renal impairment. AEs of renal function were more com-
monly reported in patients treated with dapagliflozin 10 mg
than placebo and were more frequent in older patients than
in younger patients, consistent with an increased suscep-
tibility to AEs of renal function among this age group.
Owing to their small magnitude, these changes were not
considered to be clinically meaningful. Dapagliflozin was
not associated with any electrolyte changes typical of
conventional diuretics [43], and did not increase the fre-
quency of fractures or falls, regardless of age. Previous
studies have shown that dapagliflozin does not affect bone
mineral density or markers of bone formation and resorp-
tion [44].
Dapagliflozin did not increase the risk of hyperkalaemia
compared with placebo in younger patients (aged
\65 years), although a small increase was reported in
older patients (aged C65 and C75 years). However, the
majority of cases of hyperkalaemia were not reported as
AEs. A previous pooled analysis in patients with T2DM
demonstrated that dapagliflozin did not increase the risk of
hyperkalaemia [16], although the majority of patients in
this analysis (*70 %) were aged\65 years. The higher
frequency of hyperkalaemia in older patients observed in
the current analysis may be partly related to an age-related
decline in renal function and the increased use of potas-
sium-altering medications among many older people
compared with younger people [45].
Older patients with T2DM are at considerable risk of
cardiovascular complications [5]. The data presented here
provide reassurance regarding the cardiovascular safety of
dapagliflozin and suggest a potential cardiovascular bene-
fit, which is consistent with the multifactorial beneficial
effects on cardiovascular risk factors associated with
SGLT2 inhibitors. Indeed, a recent trial in patients with
T2DM and established cardiovascular disease demon-
strated significant improvements in cardiovascular out-
comes with the SGLT2 inhibitor empagliflozin [46].
Previous studies indicate that dapagliflozin has positive
effects on a number of cardiovascular risk factors including
weight loss and blood pressure reduction [15, 47–49],
which will be further investigated in a large randomised
HR vs. control  (95% CI) 
0.726 (0.473, 1.114) 
0.879 (0.565, 1.366) 







<65 years 48/4309 42/2292 
≥65 years 47/1390 39/948 
≥75 yearsb 9/204 7/118 
Fig. 3 Cardiovascular composite endpointa by age. Data available up
to 208 weeks. An HR upper 95 % CI of \1 would indicate that
dapagliflozin was associated with longer cardiovascular composite-
free survival than control. n is the number of patients who
experienced a cardiovascular composite endpoint; N is the total
number of treated patients. CI confidence interval, DAPA dapagli-
flozin, HR hazard ratio. aCardiovascular death, myocardial infarction,
stroke and hospitalisation for unstable angina. bSubpopulation of the
C65 years age group
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placebo-controlled trial assessing cardiovascular outcomes
in a broad population of more than 17,000 patients with
T2DM and established cardiovascular disease or in patients
having multiple cardiovascular risk factors (DECLARE;
clinicaltrials.gov ID NCT01730534).
Limitations to this pooled analysis include the low
patient numbers in the C75 years age group (n = 174) in
comparison with the other two age categories (C65 years,
n = 1275;\65 years, n = 2707). In addition, although the
number of patients included in the cardiovascular meta-
analysis was larger (n = 9339), the total number of car-
diovascular events reported was low (n = 192). The gen-
eralisability of the results of this study is limited, as data on
the functional status of the patients were not available, and
the vast majority of patients in the analysis ([80 %) were
Caucasian.
5 Conclusion
This pooled post hoc analysis suggests a favourable safety
profile for dapagliflozin in older patients (aged C65 and
C75 years) with T2DM. Safety over 2 years of treatment
with dapagliflozin 10 mg was similar between older and
younger patients, with comparable rates of hypoglycaemia,
genital infections and urinary tract infections, low rates of
volume reduction and no increased risk of bone fractures.
AEs of renal function were more frequent in older patients,
the majority of which were non-serious and driven by small
transient changes in serum creatinine.
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